Orbus Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Orbus Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10969
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Orbus Therapeutics Inc (Orbus Therapeutics) is a clinical-stage biopharmaceutical company that develops and commercializes drugs for the treatment of anaplastic astrocytoma, a rare kind of cancer afflicting the central nervous system. Eflornithine, a cytostatic agent, indicated for the treatment of anaplastic glioma, is the company’s product candidate under clinical development. It is an oral solution, which can be used to treat patients with African trypanosomiasis, a sleeping sickness, besides recurrent anaplastic astrocytoma and hirsutism. Eflornithine irreversibly suppresses ornithine decarboxylase (ODC), a critical enzyme, and slows down and delays tumor growth. The company targets the treatment of central nervous system cancer and other rare cancers. Orbus Therapeutics is headquartered in Palo Alto, California, the US.

Orbus Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Orbus Therapeutics Raises USD12.5 Million in Venture Financing 10
Orbus Therapeutics Raises USD32.5 Million in Series A Financing Round 11
Partnerships 12
Orbus Therapeutics Enters into Agreement with DSG 12
Orbus Therapeutics Inc – Key Competitors 13
Orbus Therapeutics Inc – Key Employees 14
Orbus Therapeutics Inc – Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Clinical Trials 16
Jun 05, 2017: Orbus Therapeutics Announces ASCO Study Design Presentation of Pivotal Clinical Trial in Patients with Late-Stage Brain Cancer 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Orbus Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Orbus Therapeutics Raises USD12.5 Million in Venture Financing 10
Orbus Therapeutics Raises USD32.5 Million in Series A Financing Round 11
Orbus Therapeutics Enters into Agreement with DSG 12
Orbus Therapeutics Inc, Key Competitors 13
Orbus Therapeutics Inc, Key Employees 14

List of Figures
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Orbus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Orbus Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • IAC/INTERACTIVECORP:企業の戦略・SWOT・財務分析
    IAC/INTERACTIVECORP - Strategy, SWOT and Corporate Finance Report Summary IAC/INTERACTIVECORP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Electrica SA (EL):企業の財務・戦略的SWOT分析
    Electrica SA (EL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Schnell Biopharmaceuticals Inc (003060)-製薬・医療分野:企業M&A・提携分析
    Summary Schnell Biopharmaceuticals Inc (Schnell), formerly Korea Schnell Pharma Co., Ltd. is a healthcare company that offers agents and antibiotics. The company provides pharmaceutical products including amino acid infusion agents and antibiotics. Its products portfolio includes antibiotics, infusi …
  • MagForce AG (MF6):医療機器:M&Aディール及び事業提携情報
    Summary MagForce AG (MagForce) is a medical device company that offers nanotechnology-based therapy for cancer treatment. The company’s products include NanoActivator, NanoTherm, NanoPlan and NanoTherm Therapy. Its NanoActivator creates a magnetic field that can be used to treat tumors in all areas …
  • University of Oxford-製薬・医療分野:企業M&A・提携分析
    Summary University of Oxford (UO) is a research and educational university that offers student training, academic research and graduation programs. The university offers graduation courses in the various fields such as humanities, mathematical, physical and life sciences; medical sciences, and conti …
  • Camel-IDS NV:製薬・医療:M&Aディール及び事業提携情報
    Summary Camel-IDS NV (Camel-IDS) is a biotechnology company that develops radio-immunotherapeutic drugs for cancer patients. The company offers developing of compound radiopharmaceutical drugs for treatment of Her2 positive cancer. Its technology platform is based on recombinant, small antigen-bindi …
  • Australian Leaders Fund Limited:企業の戦略・SWOT・財務分析
    Australian Leaders Fund Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Leaders Fund Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • NTUC Income Insurance Co-operative Limited:企業の戦略的SWOT分析
    NTUC Income Insurance Co-operative Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Aradigm Corp (ARDM):企業の財務・戦略的SWOT分析
    Aradigm Corp (ARDM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Lloyds Banking Group Plc:戦略・SWOT・企業財務分析
    Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • OcuNexus Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary OcuNexus Therapeutics Inc (OcuNexus Therapeutics) is a development stage biopharmaceutical company engaged in novel therapeutics for unmet clinical needs in ophthalmology. It has highly differentiated, lead drug candidates based upon a novel mechanism of action such as Gap Junction Channel M …
  • Dechra Pharmaceuticals Plc (DPH):企業の財務・戦略的SWOT分析
    Summary Dechra Pharmaceuticals Plc (Dechra) is a manufacturer and distributor of veterinary pharmaceutical products. The company's product portfolio includes vetoryl, felimazole, thyforon, malaseb, canaural, isaderm, cardisure, comfortan, soludox, methoxasol, cyclospray and octacillin, among others. …
  • Samba Private Banking
    Samba Private Banking - Strategy, SWOT and Corporate Finance Report Summary Samba Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • TWi Pharmaceuticals Inc (4180):製薬・医療:M&Aディール及び事業提携情報
    Summary TWi Pharmaceuticals Inc (TWi), formerly Anchen Pharmaceuticals (Taiwan) Inc is a technology based pharmaceutical company that manufactures high barrier generics drugs. The company provides products such as donepezil hydrochloride tablets, hydroquinone cream, hydroquinone time release cream, …
  • DIC Corporation:企業の戦略・SWOT・財務分析
    DIC Corporation - Strategy, SWOT and Corporate Finance Report Summary DIC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • TMX Group Ltd (X)
    TMX Group Ltd (X) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • GI Dynamics Inc (GID):企業の財務・戦略的SWOT分析
    Summary GI Dynamics Inc (GI Dynamics) is a clinical stage medical device company that develops and commercializes endoscopy instruments. The company develops EndoBarrier, a device to treat type 2 diabetes and obesity, which is delivered endoscopically. The device imitates the mechanisms of metabolic …
  • Energy Fuels Inc (EFR):企業の財務・戦略的SWOT分析
    Energy Fuels Inc (EFR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Georgia Power Co:発電所・企業SWOT分析
    Georgia Power Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • Hycor Biomedical Inc-医療機器分野:企業M&A・提携分析
    Summary Hycor Biomedical Inc (Hycor) is a medical device company that manufactures and markets in-vitro diagnostic products. The company offers products such as auto immune testing systems, allergy testing systems, HYTEC plus and HYCOR ultrasensitive EIA products. Its auto immune testing products co …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆